Clinical Trials Logo

Clinical Trial Summary

Vertical HIV transmission has been dramatically reduced by the use of combined antiretroviral therapy in HIV-infected pregnant women. Among the most often used drugs, several have dual activity, against HIV and HBV: lamivudine, emtricitabine, tenofovir. Studies about vertical HBV transmission from HIV-HBV co-infected pregnant women are rare in developed countries. The study hypothesis is a major reduction of the risk of HBV vertical transmission.


Clinical Trial Description

Mother-to-Child HIV transmission has been dramatically reduced by the use of combined antiretroviral therapy in HIV-infected pregnant women, both in developed and in developing countries. Among the most often used drugs, several have dual activity, against HIV and HBV: lamivudine, emtricitabine, tenofovir; they can be used as a combo, as tenofovir+emtricitabine for instance. Studies about vertical HBV transmission from HIV-HBV co-infected pregnant women are rare in developed countries. The study hypothesis is a major reduction of the risk of HBV vertical transmission in this context, justifying this retrospective study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02044068
Study type Observational
Source Hopital Lariboisière
Contact
Status Completed
Phase N/A
Start date October 2014
Completion date September 2015

See also
  Status Clinical Trial Phase
Completed NCT05442437 - Clinical Study of hUC-MSCs Treating Decompensated Liver Cirrhosis With HBV Early Phase 1
Not yet recruiting NCT05951751 - The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM) N/A
Completed NCT04519710 - Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies N/A
Recruiting NCT04562051 - Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients
Recruiting NCT04683341 - Tenofovir Alafenamide in HBV Related Decompensated Liver Phase 4
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed NCT03239353 - A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects Phase 1
Recruiting NCT04904835 - Access HBV Assays - European Union (EU) Clinical Trial Protocol -
Terminated NCT04059198 - Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus Phase 2
Not yet recruiting NCT05293158 - Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study N/A
Not yet recruiting NCT05028322 - Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen Phase 2
Completed NCT02312531 - Prevention for Mother-to-infant Transmission of HBV N/A
Not yet recruiting NCT01556815 - Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma Phase 2
Recruiting NCT05786859 - The Efficacy and Safety of Rifaximin Treatment Early Phase 1
Not yet recruiting NCT06307808 - Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
Completed NCT03149627 - Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
Recruiting NCT04886336 - The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.
Recruiting NCT04568265 - A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B Phase 2
Terminated NCT02826018 - A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection Phase 1
Completed NCT01970254 - Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy